Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by consultant99on Aug 30, 2022 3:59pm
254 Views
Post# 34930564

RE:RE:Questions without answers

RE:RE:Questions without answers

Waiting three months will bring three patients from the 360 day scan column to the 450 day scan column. Agreed.

However the company is only going to submit the data for the first 25 patients. That 25th patient could be NR CR or PR. Getting BTD is a binary outcome based on the application - yes or no. From everything the company has been telling shareholders we meet the requirements based on the 90 day, 450 day and safety profile for the 24 patients that have been evaluated. 


I assume that as the trial progresses and more data becomes available the results will continue to improve. But why wait if you don't have to?

The difference between 20% for 24 patients and 25% for 25 patients at 450 shouldn't change the FDA decision on granting BTD sooner should it?

The FDA will likely see that data on the next three patients (25,26 and 27) before they have to make a final determination on BTD even if we applied after patient 24.

But what do I know? I just have questions...

<< Previous
Bullboard Posts
Next >>